Immunomodulatory effects of BRAF and MEK Inhibitors: Implications for Melanoma therapy

Melanoma and Skin Cancer

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study

Melanoma Res.

Drago JZ, Lawrence D, Livingstone E, Zimmer L, Chen T, Giobbie-Hurder A, Amann VC, Mangana J, Siano M, Zippelius A, Dummer R, Goldinger SM, Sullivan RJ

doi: 10.1097/CMR.

Melanoma and Skin Cancer

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

N Engl J Med.

Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM

doi: 10.1056/NEJMoa1708539.

Melanoma and Skin Cancer

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma

Melanoma Res

Adams AM, Chick RC, Vreeland TJ, Clifton GT, Hale DF, McCarthy PM, O'Shea AE, Bohan PMK, Hickerson AT, Park H, Sloan AJ, Hyngstrom J, Berger AC, Jakub JW, Sussman JJ, Shaheen M, Wagner T, Faries MB, Peoples GE

doi: 10.1097/CMR.0000000000000758

RECOMMENDED

Melanoma and Skin Cancer

The spectrum of cutaneous adverse events during Encorafenib and Binimetinib treatment in BRAF mutant advanced melanoma

J Eur Acad Dermatol Venereol.

Graf NP, Koelblinger P, Galliker N, Conrad S, Barysch M, Mangana J, Dummer R, Cheng PF, Goldinger SM

doi: 10.1111/jdv.15363.

Melanoma and Skin Cancer

Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma

J Natl Cancer Inst.

Audrito V, Managò A, La Vecchia S, Zamporlini F, Vitale N, Baroni G, Cignetto S, Serra S, Bologna C, Stingi A, Arruga F, Vaisitti T, Massi D, Mandalà M, Raffaelli N, Deaglio S

doi: 10.1093/jnci/djx198.

T Cells

Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity

Cancer Discov

Hong A, Piva M, Liu S, Hugo W, Lomeli SH, Zoete V, Randolph CE, Yang Z, Wang Y, Lee JJ, Lo SJ, Sun L, Vega-Crespo A, Garcia AJ, Shackelford DB, Dubinett SM, Scumpia PO, Byrum SD, Tackett AJ, Donahue TR, Michielin O, Holmen SL, Ribas A, Moriceau G, Lo RS

doi: 10.1158/2159-8290.CD-20-0873

Melanoma and Skin Cancer

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Lancet Oncol.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, International Neoadjuvant Melanoma Consortium members., Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV

doi: 10.1016/S1470-2045(19)30332-8.

Melanoma and Skin Cancer

PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma

Melanoma Res

Marcaillou M, Linder C, Chaltiel L, Sibaud V, Pagès C, Modesto A, Chira C, Dalmasso C, Boulinguez S, Bedane C, Meyer N

doi: 10.1097/CMR.0000000000000700

Psoriasis

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

J Am Acad Dermatol.

Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A

doi: 10.1016/j.jaad.2017.08.051.

Related content

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma

The spectrum of cutaneous adverse events during Encorafenib and Binimetinib treatment in BRAF mutant advanced melanoma

Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma

Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)